These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 11801557)
1. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Zou HZ; Yu BM; Wang ZW; Sun JY; Cang H; Gao F; Li DH; Zhao R; Feng GG; Yi J Clin Cancer Res; 2002 Jan; 8(1):188-91. PubMed ID: 11801557 [TBL] [Abstract][Full Text] [Related]
2. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Wakabayashi T; Natsume A; Hatano H; Fujii M; Shimato S; Ito M; Ohno M; Ito S; Ogura M; Yoshida J Neurosurgery; 2009 Mar; 64(3):455-61; discussion 461-2. PubMed ID: 19240607 [TBL] [Abstract][Full Text] [Related]
3. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Wong IH; Lo YM; Zhang J; Liew CT; Ng MH; Wong N; Lai PB; Lau WY; Hjelm NM; Johnson PJ Cancer Res; 1999 Jan; 59(1):71-3. PubMed ID: 9892188 [TBL] [Abstract][Full Text] [Related]
4. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590 [TBL] [Abstract][Full Text] [Related]
5. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. Ishiguro A; Takahata T; Saito M; Yoshiya G; Tamura Y; Sasaki M; Munakata A J Gastroenterol Hepatol; 2006 Aug; 21(8):1334-9. PubMed ID: 16872319 [TBL] [Abstract][Full Text] [Related]
6. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Wallner M; Herbst A; Behrens A; Crispin A; Stieber P; Göke B; Lamerz R; Kolligs FT Clin Cancer Res; 2006 Dec; 12(24):7347-52. PubMed ID: 17189406 [TBL] [Abstract][Full Text] [Related]
7. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Ichikawa D; Koike H; Ikoma H; Ikoma D; Tani N; Otsuji E; Kitamura K; Yamagishi H Anticancer Res; 2004; 24(4):2477-81. PubMed ID: 15330201 [TBL] [Abstract][Full Text] [Related]
8. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Lee TL; Leung WK; Chan MW; Ng EK; Tong JH; Lo KW; Chung SC; Sung JJ; To KF Clin Cancer Res; 2002 Jun; 8(6):1761-6. PubMed ID: 12060614 [TBL] [Abstract][Full Text] [Related]
9. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Zou H; Yu B; Zhao R; Wang Z; Cang H; Li D; Feng G; Yi J Zhonghua Yu Fang Yi Xue Za Zhi; 2002 Dec; 36(7):499-501. PubMed ID: 12411153 [TBL] [Abstract][Full Text] [Related]
10. Aberrant promoter hypermethylation in serum DNA from patients with silicosis. Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757 [TBL] [Abstract][Full Text] [Related]
11. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362 [TBL] [Abstract][Full Text] [Related]
12. p16INK4a methylation in serum as a follow-up marker for recurrence of colorectal cancer. Nakayama G; Kodera Y; Ohashi N; Koike M; Fujiwara M; Nakao A Anticancer Res; 2011 May; 31(5):1643-6. PubMed ID: 21617221 [TBL] [Abstract][Full Text] [Related]
13. A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients. Nakayama G; Hibi K; Nakayama H; Kodera Y; Ito K; Akiyama S; Nakao A Anticancer Res; 2007; 27(3B):1459-63. PubMed ID: 17595762 [TBL] [Abstract][Full Text] [Related]
14. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res., 8: 188-191, 2002. Widschwendter M; Jones PA Clin Cancer Res; 2002 Jan; 8(1):17-21. PubMed ID: 11801535 [No Abstract] [Full Text] [Related]
15. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. Goto T; Mizukami H; Shirahata A; Sakata M; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y; Hibi K Anticancer Res; 2009 Jan; 29(1):275-7. PubMed ID: 19331161 [TBL] [Abstract][Full Text] [Related]
16. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628 [TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681 [TBL] [Abstract][Full Text] [Related]
18. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192 [TBL] [Abstract][Full Text] [Related]
19. [Detection of free tumor-related DNA in the serum of breast cancer patients]. Zhang JJ; Ouyang T; Wan WH; Deng GR Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882 [TBL] [Abstract][Full Text] [Related]
20. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Hu XC; Wong IH; Chow LW Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]